TickerTain
$SPCX····$NVDA····$MSFT····$GOOGL····$ANTHROPIC·$TSLA····$CRWV····$NBIS····$HIMS····$TSM····$ASML····$FIGURE·$LYFT····$UBER····$SNOW····$META····$ELEVENLABS·$CURSOR·$COGNITION·$OPENAI·$AAPL····$RKLB····$XAI·$AMZN····$AMD····$000660.KS····$INTC····
← newsroom
AI Drug Discovery · AI + exhaustive biomarkers + asymmetric medicine trifecta will cure major diseases via 'prompted' therapies
now playing · AI Drug Discovery
AI Drug Discoverytailwindscore 9/10antonio linares
AI + exhaustive biomarkers + asymmetric medicine trifecta will cure major diseases via 'prompted' therapies
The convergence of deep longitudinal biomarker data (molecular to proteomic), AI models that can interpret protein-level 'coding errors', and asymmetric delivery platforms (mRNA, peptides)…
AI Drug Discoverytailwindscore 8/10antonio linares
Proprietary patient-outcome data flywheels create undisruptable moats in AI-driven healthcare platforms
Platforms that accumulate proprietary datasets of cured patient outcomes create exponential AI improvement loops: better outcomes attract more patients, generating more proprietary data, wh…
GLP-1 & Metabolic Drugstailwindscore 7/10antonio linares
GLP-1 drugs are merely the tip of the iceberg for a hundreds-of-trillions asymmetric peptide platform market
Current GLP-1 revenues (Lilly at $1T market cap) represent a tiny fraction of the addressable market for precision peptides discovered via AI-proteomic mapping. The real opportunity spans t…